Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company
23.7.2024 15:00:00 EEST | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced that it has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed contract extends through 2029 with a notable amendment that outlines a purchase commitment for two therapeutic products representing an incremental value of approximately $250 million through the end of the renewed term.
In addition, KBI, in late June, completed a successful regulatory inspection by the U.S. Food and Drug Administration (FDA) of its mammalian operation in Durham, North Carolina. This regulatory inspection enables the company’s North Carolina operations to begin providing a mammalian drug substance commercially to one of its key strategic customers. It also demonstrates KBI’s ability to act as a preferred partner for large volume commercial therapeutic manufacturing.
“As KBI continues fulfilling its commitment to our customers in helping solve their complex manufacturing challenges, this commercial contract extension allows us to demonstrate our approach as a next-generation CDMO,” said J.D. Mowery, President and CEO of KBI Biopharma. “With this agreement as well as our successful FDA regulatory inspection, we’re driving breakthroughs in biopharmaceutical development and manufacturing that help bring new therapies to market.”
He concluded, “By establishing these trusted, long-term partnerships with global pharmaceutical leaders, we’re able to positively impact the lives of patients worldwide.”
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723243720/en/
Contacts
KBI Biopharma, Inc. Company Inquiries
Sarah Wakefield
KBI Biopharma, Inc.
swakefield@kbibiopharma.com
KBI Biopharma, Inc. Media Inquiries
Kelly Biele
CG Life
kbiele@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Adds TalentSmartEQ to Advance Leadership and Business Transformation8.10.2026 17:38:00 EEST | Press release
Andersen Consulting expands its human capital capabilities through a Collaboration Agreement with TalentSmartEQ, a San Diego-based firm focused on creating practical, engaging and actionable learning experiences rooted in emotional intelligence (EQ) and leadership development. For more than two decades, TalentSmartEQ has worked with organizations around the world to develop leadership skills through emotional intelligence, helping strengthen employee engagement, teamwork, and overall performance. The firm combines research-based methodology with practical learning experiences, assessments, coaching, and customized programs that are designed to translate EQ development into sustained changes in workplace behavior. As an industry leader, TalentSmartEQ works with organizations spanning Fortune 500 companies to government agencies and privately held businesses. “Organizations are asking more of their leaders and employees as the workplace continues to evolve,” said Howard Farfel, CEO of Ta
Toluna Announces Planned CEO Transition After 25 Years; Founder Frédéric Charles Petit to remain as Board Member, Senior Advisor and Shareholder8.10.2026 17:20:00 EEST | Press release
Toluna, a global leader in consumer insights and market research technology, today announces a planned leadership transition. After 25 years leading the company he founded, Frédéric Charles Petit, Founder and Chief Executive Officer, intends to transition from his role as CEO following the appointment of his successor as part of a carefully planned succession process designed to ensure continuity for clients, employees and partners. Following the transition, Mr. Petit will continue to serve on Toluna's Board of Directors, will remain a significant shareholder of the company, and will take on an ongoing strategic advisory role for areas central to Toluna's next phase of growth. The Board, in close consultation with Mr. Petit, has initiated a structured succession process. A comprehensive transition plan is in place, including a defined handover with Mr. Petit, to ensure continuity for the company’s clients, employees, and partners. The Board expects to confirm the appointment of the com
CSC Wins for Threat Intelligence Innovation in 2026 CyberSecurity Breakthrough Awards8.10.2026 17:00:00 EEST | Press release
CSC, an enterprise-class domain registrar and world leader in detecting and mitigating brand, fraud, domain, and Domain Name System (DNS) threat vectors, today announced that its 3D Domain Security and Global Enforcement solution won for Threat Intelligence Innovation in the 10th annual CyberSecurity Breakthrough Awards. The awards recognize the most innovative companies, products, and technologies driving progress in the global information security industry. CSC’s 3D Domain Security and Global Enforcement solution for the enterprise domain ecosystem combines advanced AI machine learning technology, proprietary domain threat intelligence, expert analysis, and integrated global enforcement. With this technology, organizations can detect, understand, and act on external cyber threats targeting their brand online across social media, search engines, email, and e-commerce websites. By uncovering high-risk domains and providing a multidimensional view of threat vectors outside the firewall
Stonebranch Launches Hybrid Orchestration Control Plane to Provide Governed Reliability in the Agentic Era8.10.2026 16:00:00 EEST | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today announced the Hybrid Orchestration Control Plane, a new solution powered by Stonebranch Universal Automation Center™ (UAC) version 8.1. It lets enterprises run traditional automation, AI tasks, autonomous agents, and human decisions as one end-to-end workflow, with consistent permissions, approvals, service levels, audit trails, and recovery controls. Agents are spreading across the enterprise, but they act without the operational context around each decision: prior approvals, downstream dependencies, and recovery. Alone, they become another disconnected execution environment, with separate controls, fragmented visibility, and custom plumbing. The Hybrid Orchestration Control Plane connects them to existing automation in one governed process: agents reason and request, while governed workflows control execution. "Every enterprise will use AI agents. The question is whether those agents can be trust
INNIO and Aggreko Extend Strategic Partnership Through 2031, Securing Long-Term Engine Capacity to Meet Growing Global Power Demand8.10.2026 15:37:00 EEST | Press release
INNIO N.V. (Nasdaq: INIO) today announced a substantial extension of its long-standing strategic partnership with Aggreko, a global leader in engineered energy and temperature solutions. The extended agreement, now running through 2031, secures substantial long-term engine capacity for Aggreko while providing INNIO with additional order visibility for medium-power range engines. “Global power demand is rising rapidly, while grid constraints are growing. Together with Aggreko, we are delivering reliable, efficient, and sustainable power solutions that help bridge these gaps and keep customers moving,” said Dr. Olaf Berlien, President and CEO of INNIO. “This agreement secures proven technology and capacity to deliver reliable power wherever and whenever our customers need it,” said Sunny Thakrar, Commercial Director of Aggreko. Under the agreement, INNIO has agreed to provide a minimum of 450 MW of engine capacity in the medium-power range (Jenbacher Type 4) in 2027 and access to agreed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom